In the executive summary of the 2023 report from the 24th WHO Expert Committee on Selection and Use of Essential Medicines, the Committee recognized the worldwide impact of psoriasis and the imperative for effective treatments to address its public health significance.
Until recently, only topical psoriasis treatments were exclusively featured on the Model Lists.
In April 2023, the Committee proposed adding methotrexate to the EML and EMLc supplementary list for the new indication of psoriasis. This recommendation was made due to a favorable balance of beneficial over adverse effects, highlighting the importance of biological disease-modifying agents in managing moderate to severe psoriasis.
Read the full executive summary of the report of the 24th WHO Expert Committee on Selection and Use of Essential Medicines.
